Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Resist Updat. 2009 Jun;12(3):74-80. doi: 10.1016/j.drup.2009.03.002. Epub 2009 Apr 25.

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.

Author information

1
Tumor Hypoxia Laboratory - SAIC Frederick, Inc., NCI at Frederick, Frederick, MD 21702-1201, USA.

Abstract

Angiogenesis, a key process for the growth of human cancers, has recently been exploited for the development of a novel class of cancer therapeutics that was thought to have wide applications and not to induce resistance in the clinical setting. Indeed, anti-angiogenic therapy has become an important option for the management of several human malignancies. However, a significant number of patients either do not respond to anti-angiogenic agents or fairly rapidly develop resistance. In addition, the benefit of anti-angiogenic therapy is relatively short-lived and the majority of patients eventually relapses and progresses. Several mechanisms of resistance to anti-angiogenic therapy have been recently proposed. The current review focuses on the role of intra-tumor hypoxia as a mechanism of resistance to anti-angiogenic agents and speculates on therapeutic approaches that might circumvent resistance and thereby improve clinical outcome.

PMID:
19394890
PMCID:
PMC2696589
DOI:
10.1016/j.drup.2009.03.002
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center